FSHD guidebook series launches in English and Japanese

A new three-volume book series for people newly diagnosed with facioscapulohumeral muscular dystrophy launched ahead of World FSHD Day, with Volume 1 now available in English and Japanese. The first book aims to help patients and families understand the disease, track symptoms and prepare for medical conversations. Why it matters: - The launch gives newly diagnosed FSHD patients and their families a starting point at a time when symptoms, progression and care needs can vary widely. - The series is designed to help readers understand standard care, clinical trials and observation records before making treatment decisions with clinicians. - World FSHD Day falls on June 20, putting the release in the middle of global awareness efforts around the disease. What happened: - Masa.H, representative of Cell Healing, launched a new book series for people newly diagnosed with facioscapulohumeral muscular dystrophy and their families. - The English Kindle edition, FSHD: The First Book to Read After Diagnosis, was released on June 16, 2026. - A Japanese-language Kindle edition was released on June 17, 2026. - Volume 1 is available now, and two additional volumes are planned. - The book is available on Amazon Kindle, and the Japanese edition is available on Amazon Japan for 790 JPY. The details: - FSHD is a genetic neuromuscular disorder that commonly affects the face, shoulder girdle and upper arms. - FSHD can also involve the trunk, legs, walking, fatigue, pain, breathing, eyes, hearing, speech, swallowing and daily function. - Volume 1 is written as a first-read guide for people who want a clear starting point after diagnosis. - The book brings together medical foundations, practical questions and observation records in plain language. - The book emphasizes that medical decisions should be made with physicians and other qualified healthcare professionals. - Covered topics include symptoms in the face, shoulder girdle, arms, trunk and legs; left-right asymmetry; compensatory movement; pediatric and early-onset FSHD; breathing; eyes; hearing; heart-related issues; pain; fatigue; diagnosis and genetic testing; FSHD1; FSHD2; D4Z4; DUX4; standard care; rehabilitation; bracing; surgery; clinical trials; drug development; genetic counseling; and family considerations. - The book explains how the author approaches observation records for muscle strength, muscle mass, range of motion, movement and daily activities. - Those records are presented as observational material, not clinical trial evidence, and they do not guarantee any specific result. - The book includes a disclaimer that it is not a substitute for diagnosis, treatment, medication, rehabilitation, genetic counseling or other medical care. - The book also advises readers not to stop or change existing medical care, rehabilitation, medication, follow-up visits, clinical trial participation or any other medical plan based on the book. - Masatoshi Hihara, also identified as Masatoshi Hihara, is the representative of Cell Healing and is not a physician. - Hihara writes and publishes books that organize information for people diagnosed with neuromuscular conditions and their families. - A social media link included in the release points to Cell Healing on Instagram . Between the lines: - The series appears aimed at filling an information gap right after diagnosis, when patients may be searching for practical guidance rather than technical detail. - The focus on observation records suggests an effort to help readers track changes over time, but the release clearly separates that material from clinical evidence. - The multilingual launch signals an attempt to reach both Japanese and English-speaking audiences around a rare disease with complex care needs. What’s next: - Volume 2 is scheduled for late June 2026 and will focus on why change may be possible in FSHD, including working physical hypotheses, evaluation methods, symptom-by-symptom perspectives and how to distinguish recovery, improvement, maintenance and compensation. - Volume 3 is scheduled for early July 2026 and will focus on practical process, home care, supportive approaches, case records from the United States, Malaysia and Japan, and how to evaluate information without being misled by false hope or misinformation. - Readers are expected to use the series alongside professional medical guidance, especially for diagnosis, treatment and genetic considerations. The bottom line: - The launch is a patient-facing effort to turn a confusing diagnosis into a structured first step, with more volumes coming quickly for deeper guidance.